ERBB2 and colorectal carcinoma: Analysis of a CRC cohort in the phase IIa MyPathway basket trial reported that dual HER2-directed therapy with pertuzumab and trastuzumab in heavily pretreated metastatic CRC patients with HER2 amplification, overexpression, and/or activating mutations showed promising results, with an ORR of 32% (95% CI 20–45), and updated results in 2021 showed an ORR of 26.2% (95% CI 17.2–36.9) [118,119].